泓博医药：公司的DiOrion平台围绕药物早期研发的关键环节开展能力建设

Core Viewpoint - Hongbo Pharmaceutical (301230) is enhancing its DiOrion platform to improve early-stage drug development capabilities, focusing on modular capabilities such as molecular design, virtual screening, drug-likeness assessment, and patent risk analysis [1] Group 1 - The company is developing its DiOrion platform to address key aspects of early drug research [1] - The focus areas include molecular design, virtual screening, drug-likeness assessment, and patent risk analysis [1] - The company aims to steadily advance the application of these technologies in pharmaceutical research to improve R&D efficiency and strengthen core competitiveness [1]